The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
13 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,848,702 in first-year total cost, median $219,750.
Most frequent study sections
- Special Emphasis Panel[ZRG1 KUDS-F (54)]8
- Special Emphasis Panel[ZRG1 MDCN-B (55)]5
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN DIEGO2
- LEBRUN LABS, LLC1
- MISSISSIPPI STATE UNIVERSITY1
- OHIO STATE UNIVERSITY1
- PENNSYLVANIA STATE UNIV HERSHEY MED CTR1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Zebrafish Screens to Identify Agents which Reverse the Effects of Synthetic Opioids1R21DA055558-01A1 | SCHIEFER, ISAAC T | UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS, OH | $270,375 | ZRG1 |
| 2023 | Tissue Hypoxia and Topical Oxygen Therapy in Ocular Mustard Gas Injury1R21EY034833-01 | YIN, JIA | SCHEPENS EYE RESEARCH INSTITUTE, MA | $246,250 | ZRG1 |
| 2023 | The role of adaptive immunity in organophosphate induced CNS injury1R21NS131162-01 | ABDULLAH, LAILA | ROSKAMP INSTITUTE, INC., FL | $244,269 | ZRG1 |
| 2023 | Converting human butyrylcholinesterase into a metalloenzyme for catalytic hydrolysis of organophosphates1R21NS126163-01A1 | SHAFAAT, HANNAH SWOOD, DAVID W | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $231,370 | ZRG1 |
| 2023 | Novel oxime antidotes for an organophosphate insecticide requiring bioactivation1R21NS131159-01 | MEEK, EDWARD C | MISSISSIPPI STATE UNIVERSITY, MS | $219,750 | ZRG1 |
| 2023 | Novel behavioral screening tool for therapeutics against organophosphorus agents1R21NS132528-01 | COLLINS, EVA-MARIA SCHOETZ | SWARTHMORE COLLEGE, PA | $192,258 | ZRG1 |
| 2023 | Extracellular Vesicles derived from Mesenchymal Stem Cells as an Effective Medical Countermeasure against Mustard Induced Ocular Injury1R21EY033710-01A1 | LEE, RYANG HWA | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR, TX | $190,417 | ZRG1 |
| 2023 | Antioxidant Eye Wash Formulations to Counter Ocular Chemical Threats1R21EY033713-01A1 | LEBRUN, STEWART | LEBRUN LABS, LLC, CA | $165,000 | ZRG1 |
| 2022 | Refined uncharged Bis-Oximes for Rapid CNS Reactivation of OP-Inhibited hAChE.1R21NS120839-01A1 | RADIC, ZORAN | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $246,853 | ZRG1 |
| 2022 | Development of a protein therapeutics to counteract mustard-induced skin injury1R21AR080628-01 | LI, HAICHANG | OHIO STATE UNIVERSITY, OH | $236,251 | ZRG1 |
| 2022 | In Vivo Efficacy of Novel Uncharged Bis-Oximes in OP Poisoning Treatment1R21NS120884-01A1 | RADIC, ZORAN | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $209,834 | ZRG1 |
| 2022 | Restoring The Mechanical Properties of the Respiratory System as a Treatment of Fentanyl Overdose-Induced Hypoventilation using Kappa Agonists1R21DA053551-01A1 | HAOUZI, PHILIPPE A | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $202,950 | ZRG1 |
| 2022 | Cationic CAMKIIN nanoparticles that reduce chlorine-induced airway oxidative stress1R21ES032937-01A1 | SALEM, ALIASGER K | UNIVERSITY OF IOWA, IA | $193,125 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.